EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Acetylation in renal physiology and pathophysiology

Jian-Yu Zhang, Jun Wu, Zi-Han Chen, Shi-Yue Liu, Ping Li, Dan-Qian Chen

Frontiers in Pharmacology · 01.10.2025 · 16

DOI: 10.3389/fphar.2025.1660109 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 01.10.2025. Verfasst von Jian-Yu Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Science, Northwest University, Xi'an, Shaanxi, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 288 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The kidney, one of the most important organs in the human body, is vital for maintaining overall health and homeostasis. However, kidney diseases, including acute kidney injury (AKI) and chronic kidney disease (CKD), have become serious global public health issues. Post-translational modification (PTM) of proteins, especially acetylation, can affect the pathophysiology of the kidney through various pathways, including the regulation of inflammatory responses, fibrosis, apoptosis, and autophagy. Acetylation is primarily regulated by two enzymes: histone acetyltransferases (HATs) and histone deacetylases (HDACs). There are 11 known HDAC isoforms that influence the onset and progression of kidney disease by affecting the acetylation level of key proteins. Additionally, sirtuins (SIRTs), which belonging to class III HDACs, regulate multiple biological processes to exert protective effects on the kidneys and delay the progression of kidney diseases. Intriguingly, some SIRTs exhibit dual roles (protective/detrimental) in various renal disease models. Many HDAC inhibitors and SIRT activators have been widely used in the clinical treatment of various kidney diseases. In this review, we summarize the roles and mechanisms of HDACs and SIRTs in kidney diseases and then review the potential therapeutic effects of some SIRT activators and HDAC inhibitors in kidney protection. Notably, we also discuss the mechanism of SIRTs with dual roles in kidney protection and injury and introduce some agonists and inhibitors targeting these SIRTs.

Schlagwörter

Stichwörter der Autor:innen

AKIAcetylationCKDHDACsSIRTs

Autor:innen und Institutionen

  • School of Life Science, Northwest University, Xi'an, Shaanxi, China.
  • Office of Research Administration, Shandong College of Traditional Chinese Medicine, Yantai, Shandong, China.
  • Beijing Key Lab for Immune-Mediated Inflammatory Diseases, Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, China.

Zitieren

APA

Zhang, J. Y., Wu, J., Chen, Z. H., Liu, S. Y., Li, P., & Chen, D. Q. (2025). Acetylation in renal physiology and pathophysiology. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1660109

Vancouver

Zhang JY, Wu J, Chen ZH, Liu SY, Li P, Chen DQ. Acetylation in renal physiology and pathophysiology. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1660109

BibTeX
@article{Zhang2025,
  author = {Zhang, Jian-Yu and Wu, Jun and Chen, Zi-Han and Liu, Shi-Yue and Li, Ping and Chen, Dan-Qian},
  title = {Acetylation in renal physiology and pathophysiology},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1660109}
}
Kostenlos starten →